Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational cohort study
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Olmesartan, a widely used angiotensin II receptor blocker (ARB), has been linked to sprue-like enteropathy. No cases of olmesartan-associated enteropathy have been reported in Northeast Asia. We investigated the associations between olmesartan and other ARBs and the incidence of enteropathy in Korea. Methods: Our retrospective cohort study used data from the Korean National Health Insurance Service to identify 108,559 patients (58,186 females) who were initiated on angiotensin converting enzyme inhibitors (ACEis), olmesartan, or other ARBs between January 2005 and December 2012. The incidences of enteropathy were compared among drug groups. Changes in body weight were compared after propensity score matching of patients in the ACEis and olmesartan groups. Results: Among 108,559 patients, 31 patients were diagnosed with enteropathy. The incidences were 0.73, 0.24, and 0.37 per 1,000 persons, in the ACEis, olmesartan, and other ARBs groups, respectively. Adjusted rate ratios for enteropathy were: olmesartan, 0.33 (95% confidential interval [CI], 0.10 to 1.09; p = 0.070) and other ARBs, 0.34 (95% CI, 0.14 to 0.83; p = 0.017) compared to the ACEis group after adjustment for age, sex, income level, and various comorbidities. The post hoc analysis with matched cohorts revealed that the proportion of patients with significant weight loss did not differ between the ACEis and olmesartan groups. Conclusions: Olmesartan was not associated with intestinal malabsorption or significant body weight loss in the general Korean population. Additional largescale prospective studies of the relationship between olmesartan and the incidence of enteropathy in the Asian population are needed.
Abstract
Background/Aims: Olmesartan, a widely used angiotensin II receptor blocker (ARB), has been linked to sprue-like enteropathy. No cases of olmesartan-associated enteropathy have been reported in Northeast Asia. We investigated the associations between olmesartan and other ARBs and the incidence of enteropathy in Korea. Methods: Our retrospective cohort study used data from the Korean National Health Insurance Service to identify 108,559 patients (58,186 females) who were initiated on angiotensin converting enzyme inhibitors (ACEis), olmesartan, or other ARBs between January 2005 and December 2012. The incidences of enteropathy were compared among drug groups. Changes in body weight were compared after propensity score matching of patients in the ACEis and olmesartan groups. Results: Among 108,559 patients, 31 patients were diagnosed with enteropathy. The incidences were 0.73, 0.24, and 0.37 per 1,000 persons, in the ACEis, olmesartan, and other ARBs groups, respectively. Adjusted rate ratios for enteropathy were: olmesartan, 0.33 (95% confidential interval [CI], 0.10 to 1.09; p = 0.070) and other ARBs, 0.34 (95% CI, 0.14 to 0.83; p = 0.017) compared to the ACEis group after adjustment for age, sex, income level, and various comorbidities. The post hoc analysis with matched cohorts revealed that the proportion of patients with significant weight loss did not differ between the ACEis and olmesartan groups. Conclusions: Olmesartan was not associated with intestinal malabsorption or significant body weight loss in the general Korean population. Additional largescale prospective studies of the relationship between olmesartan and the incidence of enteropathy in the Asian population are needed.
참고문헌 (23)
- Scott LJ, "Olmesartan medoxomil : a review of its use in the management of hypertension", Drugs, 68, pp.1239~1272 (2008)
- Rubio-Tapia A, "Severe spruelike enteropathy associated with olmesartan", Mayo Clin Proc, 87, pp.732~738 (2012)
- Burbure N, "Olmesartan-associated sprue-like enteropathy : a systematic review with emphasis on histopathology", Hum Pathol, 50, pp.127~134 (2016)
- Bhat N, "Olmesartan-related sprue-like enteropathy", Indian J Gastroenterol, 33, pp.564~567 (2014)
- Cyrany J, "Letter: telmisartan-associated enteropathy. Is there any class effect?", Aliment Pharmacol Ther, 40, pp.569~570 (2014)
- Herman ML, "A case of severe sprue-like enteropathy associated with valsartan", ACG Case Rep J, 2, pp.92~94 (2015)
- "Safety information" (2013)[URL]
- Basson M, "Severe intestinal malabsorption associated with olmesartan : a French nationwide observational cohort study", Gut, 65, pp.1664~1669 (2016)
- Cummins AG, "Prevalence of celiac disease in the Asia-Pacific region", J Gastroenterol Hepatol, 24, pp.1347~1351 (2009)
- Kwon S, "Payment system reform for health care providers in Korea", Health Policy Plan, 18, pp.84~92 (2003)
- Lee J, "Cohort profile : the National Health Insurance Service-National Sample Cohort(NHIS-NSC), South Korea", Int J Epidemiol, 46, pp.e15~ (2017)
- Wallace JI, "Involuntary weight loss in older outpatients : incidence and clinical significance", J Am Geriatr Soc, 43, pp.329~337 (1995)
- Stuart EA, "Matching methods for causal inference : a review and a look forward", Stat Sci, 25, pp.1~21 (2010)
- Ianiro G, "Systematic review : sprue-like enteropathy associated with olmesartan", Aliment Pharmacol Ther, 40, pp.16~23 (2014)
- Marthey L, "Olmesartan-associated enteropathy : results of a national survey", Aliment Pharmacol Ther, 40, pp.1103~1109 (2014)
- Naranjo CA, "A method for estimating the probability of adverse drug reactions", Clin Pharmacol Ther, 30, pp.239~245 (1981)
- Greywoode R, "Olmesartan, other antihypertensives, and chronic diarrhea among patients undergoing endoscopic procedures : a case-control study", Mayo Clin Proc, 89, pp.1239~1243 (2014)
- Haller H, "Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes", N Engl J Med, 364, pp.907~917 (2011)
- Padwal R, "Comparative effectiveness of olmesartan and other angiotensin receptor blockers in diabetes mellitus : retrospective cohort study", Hypertension, 63, pp.977~983 (2014)
- DiGiacomo D, "Human leukocyte antigen DQ2", 8 prevalence in non-celiac patients with gastrointestinal diseases, 2013, pp.19, 2507~2513
- 권태근, "Celiac Disease 1예", 대한소화기학회지, 61(6), pp.338~342 (2013), 대한소화기학회
- 황인경, "Celiac Disease in a Predisposed Subject (HLA-DQ2.5) with Coexisting Graves’ Disease", Endocrinology and Metabolism, 30(1), pp.105~109 (2015), 대한내분비학회
- Malandrino N, "Metabolic and nutritional features in adult celiac patients", Dig Dis, 26, pp.128~133 (2008)